Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that on July 15,...
Author:
Publish date:

NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that on July 15, 2020, the compensation committee of Seelos' board of directors approved the grant of a stock option to purchase 50,000 shares of common stock to one new employee.  The stock option was granted as inducements material to the new employee entering into employment with Seelos in accordance with Nasdaq Listing Rule 5635(c)(4). 

The stock option has an exercise price equal to $1.01, the closing price per share of Seelos' common stock, as reported by Nasdaq, on July 15, 2020, the date of grant. The option is a non-qualified stock option and 1/4th of the shares subject to the option vest on the one-year anniversary of the grant date and an additional 1/48th of the shares subject to the option vest monthly thereafter over the next three years, in each case provided that the new employee remains continuously employed by Seelos through the applicable vesting date, inclusive.

Seelos is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward-looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the employees and equity plans. Risks and uncertainties include risks associated with the Company's employees and equity plans, and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.  

Contact Information: Anthony MarcianoHead of Corporate CommunicationsSeelos Therapeutics, Inc. (Nasdaq: SEEL)300 Park Ave., 12th Fl. New York, NY 10022(646) 293-2136 anthony.marciano@seelostx.com www.seelostherapeutics.com https://twitter.com/seelostx https://www.linkedin.com/company/seelos

View original content: http://www.prnewswire.com/news-releases/seelos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301095137.html

SOURCE Seelos Therapeutics, Inc.